Combinatorial Cancer Immunotherapies

被引：87
作者：
Hellmann, Matthew D. [1 ,2 ]
Friedman, Claire F. [1 ,2 ]
Wolchok, Jedd D. [1 ,2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Weill Cornell Med Coll, New York, NY USA
来源：
TUMOR IMMUNOLOGY | 2016年 / 130卷
关键词：
REGULATORY T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; DOUBLET CHEMOTHERAPY; METASTATIC MELANOMA; ANTITUMOR IMMUNITY; PD-1; BLOCKADE; DOUBLE-BLIND; DILATED CARDIOMYOPATHY; NIVOLUMAB ANTI-PD-1; BIOLOGICAL APPROACH;
D O I：
10.1016/bs.ai.2015.12.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
T cell checkpoint blockade therapies are revolutionizing the treatment of patients with cancer. Highlighted by the recent success of PD-1 plus CTLA-4 blockade in patients with melanomas, synergistic immunotherapy combinations of modalities represent an important opportunity to improve responses and outcomes for patients. We review the rationale and experience with T cell checkpoint blockade in combination with targeting of other coinhibitory or costimulatory checkpoints, immunomodulatory molecules in the tumor microenvironment, and other anticancer modalities such as vaccines, chemotherapy, and radiation.
引用
收藏
页码：251 / 277
页数：27
相关论文
共 171 条
  • [1] Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
    Agata, Y
    Kawasaki, A
    Nishimura, H
    Ishida, Y
    Tsubata, T
    Yagita, H
    Honjo, T
    [J]. INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) : 765 - 772
  • [2] OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand
    AlShamkhani, A
    Birkeland, ML
    Puklavec, M
    Brown, MH
    James, W
    Barclay, AN
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (08) : 1695 - 1699
  • [3] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
    Andtbacka, Robert H. I.
    Kaufman, Howard L.
    Collichio, Frances
    Amatruda, Thomas
    Senzer, Neil
    Chesney, Jason
    Delman, Keith A.
    Spitler, Lynn E.
    Puzanov, Igor
    Agarwala, Sanjiv S.
    Milhem, Mohammed
    Cranmer, Lee
    Curti, Brendan
    Lewis, Karl
    Ross, Merrick
    Guthrie, Troy
    Linette, Gerald P.
    Daniels, Gregory A.
    Harrington, Kevin
    Middleton, Mark R.
    Miller, Wilson H., Jr.
    Zager, Jonathan S.
    Ye, Yining
    Yao, Bin
    Li, Ai
    Doleman, Susan
    VanderWalde, Ari
    Gansert, Jennifer
    Coffin, Robert S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) : 2780 - U98
  • [4] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
    Ansell, Stephen M.
    Lesokhin, Alexander M.
    Borrello, Ivan
    Halwani, Ahmad
    Scott, Emma C.
    Gutierrez, Martin
    Schuster, Stephen J.
    Millenson, Michael M.
    Cattry, Deepika
    Freeman, Gordon J.
    Rodig, Scott J.
    Chapuy, Bjoern
    Ligon, Azra H.
    Zhu, Lili
    Grosso, Joseph F.
    Kim, Su Young
    Timmerman, John M.
    Shipp, Margaret A.
    Armand, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) : 311 - 319
  • [5] Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.
    Antonia, Scott Joseph
    Goldberg, Sarah B.
    Balmanoukian, Ani Sarkis
    Sanborn, Rachel E.
    Steele, Keith
    Narwal, Rajesh
    Robbins, Paul B.
    Gu, Yu
    Karakunnel, Joyson Joseph
    Rizvi, Naiyer A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).
    Antonia, Scott Joseph
    Brahmer, Julie R.
    Gettinger, Scott N.
    Chow, Laura Quan Man
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott Andrew
    Gerber, David E.
    Goldman, Jonathan Wade
    Shen, Yun
    Harbison, Christopher
    Alaparthy, Suresh
    Chen, Allen C.
    Borghaei, Hossein
    Rizvi, Naiyer A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.
    Antonia, Scott Joseph
    Gettinger, Scott N.
    Chow, Laura Quan Man
    Juergens, Rosalyn A.
    Borghaei, Hossein
    Shen, Yun
    Harbison, Christopher
    Chen, Allen C.
    Ready, Neal
    Rizvi, Naiyer A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Antonia SJ, 2015, ASCO M, V33, P7503, DOI DOI 10.1200/JC0.2015.33.15_
  • [9] Arestides RSS, 2002, EUR J IMMUNOL, V32, P2874, DOI 10.1002/1521-4141(2002010)32:10<2874::AID-IMMU2874>3.0.CO
  • [10] 2-4
12345678910